Excellence in Research and Development

Sylvie Binda began her R&D career in a CNRS/University mixed lab at Metz University where she spent three years focusing on the key role of microbes in the remediation of wastewater and polluted soils, and teaching microbiology, bioprocesses and fermentation science to University students (from bachelor to master’s degree).

She then moved into the private sector, focusing on bioprocesses, GMO building strategy and fermentation science development for Essential Amino Acids bioproduction (7 years between Japan and France at Ajinomoto), and probiotics and microbiome discoveries (12 years at Danone Research in different key R&D positions).

She is currently managing a complete translational approach (from bench to market) for classical and next-generation-probiotics as the R&D Vice President at Lallemand Health Solutions, building and managing a new department of over 40  researchers with an active human demonstration program.

Sylvie is a recognized expert in the probiotics and health sector with a strong knowledge of probiotics and microbiome science, with experience in both the public and private sectors. She currently has or has had various key opinion leader roles in associations for collective mobilization and intelligence on microbiome and probiotics science: EMIH, IPA, IPAEU, HMA, PRI, ILSI, ISAPP, HARMI, Horizons projects, Ferments du Futur, and many more.

Stéphane Bronner is the Director of Translational Research at Lallemand Health Solutions. He earned his Ph.D. in molecular biology and microbiology from the University of Strasbourg, France, in 2002. His doctoral research focused on the expression and regulation of Staphylococcus aureus toxins. He also collaborated with various pharmaceutical companies on projects involving both existing and new antimicrobial molecules.

With over two decades of experience in research and development project management, as well as cross-functional team leadership in contract development and manufacturing companies in France, he has been instrumental in preclinical projects, including pharmacokinetics, pharmacodynamics, efficacy studies, and the development and manufacturing of new investigational products for clinical trials.

In 2018, after serving as Site Director for at a pharmaceutical‑supporting CDMO in Montpellier, France, he relocated to Montreal to take on the role of Production Manager at Lallemand Health Solutions.

He became part of the Lallemand Health Solutions R&D Team in 2021, leading efforts in -biotics discovery and characterization, development, and translational science, working closely with various cross-functional teams.

Marie-Laure is the Director of Clinical Operations at Lallemand Health Solutions. She has over 15 years of experience in clinical research and project management within the personal care and probiotics industries. In her current role, she manages Lallemand Health Solutions’ clinical studies portfolio to understand microbiome modulations and generate strong scientific data on their proprietary probiotic strains for various health applications.

Marie-Laure also serves as the President of the Association québécoise des infirmières et intervenants en recherche clinique (AQIIRC), a clinical research organization dedicated to supporting best practices and research excellence.

She is a Biotechnology Engineer (Ecole des Bio-Industries - France), holds a Graduate Diploma in Management (HEC Montreal - Canada), and is a Certified Clinical Research Professional (CCRP) from SOCRA.

Stéphanie Gazagne is the Director of Bioprocess and Galenic development at Lallemand Health Solutions. She first integrated Lallemand as an intern and is still part of the company after more than 15 years. She is an Engineer for the food industry (ENSBANA / L’institut Agro – Dijon, France), specialized in industrial microbiology and biotechnology. She spent over 7 years focusing on the optimization of bacteria processes to increase shelf-life and yield other enhancements to overall cell quality. She also led the integration of new measurement tools and procedures (e.g., flow cytometry, physiological state markers, etc.) to get a better understanding of bacteria behavior during their processing. She was managing R&D bioprocess activities for Lalleamand Health Solutions before taking on the direction of both Bioprocess & Galenic teams in 2025, merging both activities in a unique platform developing the whole process production of health solutions.